Caplin Point Laboratories Q4 FY26 Results: PAT of Rs 170.11 crore (up 17.9% YoY) Pharmaceuticals – Latin America Generic Formulations
- May 15, 2026
- Posted by: Kashish Aggarwal
- Category: News
Caplin Point Laboratories results were announced on May 14, 2026, at the company’s board meeting. the company PAT was Rs 170.11 crore (+17.9% YoY from Rs 144.32 crore). Revenue Rs 628.52 crore (+19% YoY from Rs 528.19 crore). FY26 annual PAT Rs 641.24 crore (+19.6% from Rs 536.31 crore). FY26 revenue Rs 2,302.73 crore (+13.2%). FY26 EPS Rs 84.11 vs Rs 70.25. Strong execution in regulated Latin American markets continues. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Caplin Point Laboratories Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 170.11 crore | Q4 FY25 / Reference | up 17.9% YoY from Rs 144.32 crore |
| Revenue from Operations | Rs 628.52 crore | Q4 FY26 Revenue | up 19% YoY from Rs 528.19 crore |
| Ticker | CAPLIPOINT | Sector: Pharmaceuticals – Latin America Generic Formulations |
Screen the best stocks on the Univest Screener.
Caplin Point Laboratories Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. the company PAT was Rs 170.11 crore (+17.9% YoY from Rs 144.32 crore). Revenue Rs 628.52 crore (+19% YoY from Rs 528.19 crore). FY26 annual PAT Rs 641.24 crore (+19. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Caplin Point Laboratories FY27 Outlook
Post Caplin, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharmaceuticals – Latin America Generic Formulations space. The Caplin results demonstrate the company’s execution capabilities. Track Caplin updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Caplin Point Laboratories Q4 FY26 Results
What is Caplin Point Laboratories Q4 FY26 PAT?
Ans. Caplin Point Laboratories Q4 FY26 profit after tax was Rs 170.11 crore, up 17.9% YoY from Rs 144.32 crore in Q4 FY25..
When did Caplin Point Laboratories announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Caplin Point Laboratories?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharmaceuticals – Latin America Generic Formulations sector. Track live updates on the Univest Screener.
Where can I track Caplin Point Laboratories Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
